WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

Firm News

On January 29, 2018, Ocular Therapeutix™, Inc. (NASDAQ: OCUL) announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share. The shares of common stock issued and sold in the offering at the closing include 975,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The offering was made pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission. All of the shares in the offering were sold by Ocular.

WilmerHale's Brian Johnson advised Ocular in this transaction with a team that included Ryan Mitteness, Michael Raine, Avery Reaves, Jasmine Haddad and Heidi Treiber.

Ocular's press release is available at www.ocutx.com.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.